American company Johnson & Johnson has withdrawn its application for early approval in India for its anti-corona vaccine. However, the company has not made public the reason behind this move. Indian drug regulator DCGI gave this information on Monday. They had applied for trials of its vaccine in India in April this year.
There has also been no official comment from the company regarding this. India currently faces legal challenges with vaccine manufacturers over issues of protection against harm. Minister of State for Health Bharti Praveen Pawar had said in the past that they have formed a team to hold talks with vaccine manufacturers. These issues are with Pfizer, Moderna and Johnson & Johnson.
Moderna’s vaccine got permission for emergency use in June
So far, India has allowed four anti-coronavirus vaccines. These include Bharat Biotech’s indigenous vaccine Covaxin, Oxford-AstraZeneca’s Covishield, Russia’s Sputnik V and Moderna’s vaccine. The vaccine of American company Moderna also got permission for emergency use by DCGI in June itself.
Bharat Biotech’s Covaxin Effective against Delta Plus variants
A study has revealed that Bharat Biotech’s anti-coronavirus vaccine Covaxin is effective against the delta plus variant of this virus. ICMR has published this study. This variant also first appeared in India and 20 other countries in April. However, this study is yet to be peer reviewed.